Norway -
Norwegian -
Statens legemiddelverk
tiopental life medical 0.5 g
life medical aps (1) - tiopentalnatrium - pulver til injeksjonsvæske, oppløsning - 0.5 g
Norway -
Norwegian -
Statens legemiddelverk
tiopental life medical 1 g
life medical aps (1) - tiopentalnatrium - pulver til injeksjonsvæske, oppløsning - 1 g
Norway -
Norwegian -
Statens legemiddelverk
toradol 30 mg/ ml
atnahs pharma netherlands b.v. - ketorolaktrometamol - injeksjonsvæske, oppløsning - 30 mg/ ml
Norway -
Norwegian -
Statens legemiddelverk
toradol 30 mg/ ml
2care4 aps - ketorolaktrometamol - injeksjonsvæske, oppløsning - 30 mg/ ml
Norway -
Norwegian -
Statens legemiddelverk
vallergan 5 mg/ ml
sanofi-aventis norge (3) - alimemazinhemitartrat - mikstur, oppløsning - 5 mg/ ml
Norway -
Norwegian -
Statens legemiddelverk
vallergan 10 mg
sanofi-aventis norge (3) - alimemazinhemitartrat - tablett, filmdrasjert - 10 mg
Norway -
Norwegian -
Statens legemiddelverk
hypotron 5 mg
brancaster pharma ireland ltd. - midodrinhydroklorid - tablett - 5 mg
Norway -
Norwegian -
Statens legemiddelverk
hypotron 2.5 mg
brancaster pharma ireland ltd. - midodrinhydroklorid - tablett - 2.5 mg
Norway -
Norwegian -
Statens legemiddelverk
uvadex 20 mikrog/ ml
therakos europe ltd - metoksalen - oppløsning til blodfraksjonsmodifisering - 20 mikrog/ ml
European Union -
Norwegian -
EMA (European Medicines Agency)
sarclisa
sanofi winthrop industrie - isatuximab - multippelt myelom - antineoplastiske midler - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.